A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.

@article{Steurer2017ALO,
  title={A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.},
  author={Michael A. Steurer and Philippe Quittet and Helen A. Papadaki and Dominik L D Selleslag and J. F. Viallard and Georgia D. Kaiafa and Ann Janssens and Tom{\'a}{\vs} Koz{\'a}k and Hans Wadenvik and Marieke Wilma Schoonen and Laura Belton and Georg Kreuzbauer},
  journal={European journal of haematology},
  year={2017},
  volume={98 2},
  pages={112-120}
}
OBJECTIVE Romiplostim has maintained long-term platelet counts in patients with immune thrombocytopenia (ITP) for up to 5 yr in clinical studies. This prospective observational study aimed to describe romiplostim utilisation and outcomes in European clinical practice. METHODS Adults with primary ITP who received romiplostim in routine care were eligible. RESULTS Three-hundred and forty patients were eligible for analysis, of whom 299 (88%) completed the 2-yr observation period. The median… CONTINUE READING